GSK stays strong as healthy sales beat expectations
Reuters
Published Apr 26, 2023 02:11AM ET
Updated Apr 26, 2023 08:25AM ET
By Natalie Grover and Maggie Fick
LONDON (Reuters) -GSK began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results thanks to strong sales of its vaccines as well as HIV and respiratory medicines.
The company reaffirmed its guidance for 2023, saying it expected adjusted operating profit growth to be higher in the second half but lower in the first half of the year when expected drug launches will increase costs.
In recent quarters the British drugmaker, which carved out its consumer health business Haleon last year, has begun to reverse years of underperformance relative to its peers and bounce back after largely missing out on the market for COVID-19 vaccines.
Even after stripping out one-off contributions, underlying revenue and earnings beat expectations by a respectable 3% and 4% respectively, Citi analyst Andrew Baum wrote in a note.
These are solid results for GSK investors, said Lucy Coutts, investment director at wealth management firm JM Finn, which holds GSK shares.
Baum added that there was little material risk to GSK's near-term earnings, though investors are nervous ahead of a trial in California for Zantac, a discontinued heartburn drug that claimants say is linked to cancer.
Some of those fears were quashed in December after a U.S. judge dismissed about 50,000 claims in federal court.
That does not directly affect tens of thousands of similar cases pending in state courts and a trial in July will be the first test of how Zantac cancer claims fare before a jury.
Investors are also concerned about the company's long-term prospects, given the pending loss of patent protection on one of GSK's HIV compounds and setbacks in its marketed oncology portfolio.
To compensate, the company has announced a number of buyout deals, including Bellus Health, Affinivax and Sierra Oncology (NASDAQ:SRRA).
The company intends to continue shopping, CEO Emma Walmsley said in a post-earnings call.
GSK is also relying in part on its potential blockbuster vaccine for RSV, which leads to thousands of hospitalisations and deaths each year.
It expects to launch the vaccine this year in the U.S. and Europe, pending regulatory approval, as does rival Pfizer (NYSE:PFE) with its own RSV vaccine.
Get The News You Want
($1 = 0.8039 pounds)
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.